{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T13:43:14Z","timestamp":1789911794077,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jhep.2016.08.021","type":"journal-article","created":{"date-parts":[[2016,9,12]],"date-time":"2016-09-12T17:49:50Z","timestamp":1473702590000},"page":"39-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients"],"prefix":"10.1016","volume":"66","author":[{"given":"Stanislas","family":"Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bourliere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Lucier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Hezode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dorival","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Larrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor D.E.","family":"Ledinghen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Metivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Zarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guyader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Minello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thabut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Chazouilleres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"Riachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Bourcier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mathurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"D\u2019Alteroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fouchard-Hubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Habersetzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Causse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Geist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Gournay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Saillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ventzislava","family":"Petrov-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alpha","family":"Diallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Fontaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2016.08.021_b0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2016.08.021_b0010","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BS-790052 in an in vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2016.08.021_b0015","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-d-2\u2019-deoxy-2\u2019-alfa-fluoro-2\u2019-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.jhep.2016.08.021_b0020","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","article-title":"Assessment of pharcokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir","volume":"18","author":"Bifano","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.08.021_b0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3851\/IMP2718","article-title":"Effect of coadministration of daclatasvir on the pharmacokinetics of combined oral contraceptive containing ethynil estradiol and norgestimate","volume":"19","author":"Bifano","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2016.08.021_b0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0040","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0050","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0055","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","article-title":"All-oral 12 week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study","volume":"61","author":"Nelson","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.021_b0060","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jama.2014.7734","article-title":"Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection","volume":"312","author":"Sulkowski","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2016.08.021_b0065","first-page":"87A(A195)","article-title":"Sofosbuvir and ribavirin therapy for the treatment of HIV\/HCV coinfected patients with HCV GT 1\u20134 infection: the photon 1 and 2 trials","volume":"60S","author":"Rockstroh","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.021_b0070","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus Ribavirin for treatment of hepatitis C virus in patients coinfected with HIV (PHOTON-2): a multicentre, open-label, non-randomised study","volume":"385","author":"Molina","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2016.08.021_b0075","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus Sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"Wyles","year":"2015","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2016.08.021_b0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1053\/j.gastro.2014.10.001","article-title":"Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis virus infection after liver transplantation","volume":"148","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2016.08.021_b0085","unstructured":"AASLD HCV guidance: Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org."},{"key":"10.1016\/j.jhep.2016.08.021_b0090","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. Available at: www.easl.eu\/research\/ow-contributions\/clinical-practice-guidelines\/detail\/recommendations-on-treatment-of hepatitis C, 2015."},{"key":"10.1016\/j.jhep.2016.08.021_b0095","first-page":"134A(A982)","article-title":"Sofosbuvir plus ribavirin for the treatment of russian patients with chronic HCV genotype 1 or 3 infection","volume":"60S","author":"Chulanov","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.021_b0100","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C infection in patients of Egyptian ancestry","volume":"62","author":"Ruane","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.021_b0105","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.021_b0110","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/liv.12774","article-title":"Eligibility and safety of the first IFN-free therapy against hepatitis C in a real-world setting","volume":"35","author":"H\u00f6ner Zu Siederdissen","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.08.021_b0115","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/ajt.12209","article-title":"Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C","volume":"13","author":"Fontana","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jhep.2016.08.021_b0120","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.dld.2014.06.004","article-title":"Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late","volume":"46","author":"Pellicelli","year":"2014","journal-title":"Dig Liv Dis"},{"key":"10.1016\/j.jhep.2016.08.021_b0125","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.cgh.2015.05.030","article-title":"Efficacy of Sofosbuvir and Daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation","volume":"13","author":"Leroy","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2016.08.021_b0130","first-page":"55A(A46)","article-title":"Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population","volume":"S60","author":"Dieterich","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2016.08.021_b0135","first-page":"S183(A007)","article-title":"All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-Target real world experience","volume":"S62","author":"Reddy","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.021_b0140","doi-asserted-by":"crossref","first-page":"S263(LP08)","DOI":"10.1016\/S0168-8278(15)30162-8","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: real-world experience from HCV-Target","volume":"62","author":"Saxena","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2016.08.021_b0145","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","article-title":"Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomized, double-blind, phase 2 trial (SIRIUS)","volume":"15","author":"Bourli\u00e8re","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2016.08.021_b0150","article-title":"The impact of ledipasvir\/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study","author":"Younossi","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2016.08.021_b0155","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28491","article-title":"Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen","volume":"63","author":"H\u00e9zode","year":"2016","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781630486X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016882781630486X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T20:32:25Z","timestamp":1771965145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016882781630486X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S016882781630486X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2016.08.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2016.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}